到2025年,爱尔兰的HSE为80,000名病人花费了2,000万欧元的重量损失药物,其使用情况因地区而异,而且正在对新药物进行审查。 Ireland’s HSE spent €200M on weight-loss drugs for 80,000 patients by 2025, with usage varying by region and ongoing review of new drugs.

2025年,卫生服务执行部门每天花费约550 000欧元,用在Ozempic和Saxenda等减重药物上,在不到三年的时间里,总共花费了2亿欧元。 The Health Service Executive (HSE) spent about €550,000 daily on weight-loss drugs like Ozempic and Saxenda in 2025, totaling over €200 million in under three years. 大约80,000名病人通过免费药品计划获得药品,比2023年增加了34%。 Around 80,000 patients received the medications through free drug schemes, a 34% increase since 2023. Ozempic只为糖尿病提供资金,尽管在减肥方面普遍使用非标签用途,而Saxenda则被批准进行体重管理。 Ozempic is only funded for diabetes, despite widespread off-label use for weight loss, while Saxenda is approved for weight management. 使用率因地区而异,Kildare和West Wicklow、北都柏林和Galway的数字最高,West Cork、Roscommon和Dun Laoghaire的数字最低。 Usage varied by region, with Kildare and West Wicklow, North Dublin, and Galway having the highest numbers, and West Cork, Roscommon, and Dun Laoghaire the lowest. HSE正在审查是否在偿还清单上增加其他GLP-1类药物,如Mounjaro和Wegovy,并列举了对成本和数据透明度的关切。 The HSE is reviewing whether to add other GLP-1 drugs like Mounjaro and Wegovy to the reimbursed list, citing concerns over cost and data transparency.